Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
SolarEdge (SEDG) - Enter on Strength, Backstop on Execution
Operational recovery and durable demand justify a tactical long; use a disciplined entry, stop and tiered targets.
SolarEdge's core inverter and optimizer franchise is back to revenue growth after a rocky 2024-2025 stretch. Recent quarterly revenue acceleration, im...
JPMorgan: Balance-Sheet Leverage, Strong Cash Generation, and an Aggressive Path to $405
RWA optionality is the upside lever; earnings power and capital returns make a compelling long with a clear entry, stop and $405 target.
JPMorgan’s cash-generation and large equity base create high optionality for accelerating capital returns if management pursues RWA optimization. We...
Ducommun: One-Off Settlement Clouds an Otherwise Clean Earnings Story - Tactical Short Idea
Q3 headline loss looks scary on the surface, but operating cash and pre-settlement results show durable earnings; we downgrade to a tactical short given legal/settlement uncertainty and stretched valuation
Ducommun reported a Q3 (fiscal) loss driven by a large other operating charge consistent with a settlement. Under the hood the business still generate...
Short the Momentum: Sandisk Looks Crowded Ahead of Q2 — A Tactical Short Into Earnings
Fast recovery in results and a massive run-up have priced in tight NAND markets — trade the pullback, not the narrative.
Sandisk's recent earnings showed a dramatic operational recovery, but the stock has already priced in a large slice of the NAND rally. With signs of c...
Primerica (PRI) — Buy the Pullback as Affordability Fears Fade
Strong cash flow, rising dividends and improving fundamentals make PRI a tactical long while downside is contained by capital returns and balance-sheet strength.
Primerica delivered a clean Q3 (ended 09/30/2025): revenues $839.9M (+8.5% YoY), net income $206.8M and operating cash flow $202.9M. With a steadily r...
Micron’s AI Memory Boom Is Bigger Than I Expected - Tactical Long Setup
Q1 strength, pricing power and HBM demand justify a measured long with defined entry, stops and targets.
Micron just reported a blowout fiscal Q1 (ended 11/27/2025) with revenue of $13.64B, net income of $5.24B and operating cash flow of $8.41B — number...
Chevron: Cash-Rich Oil Major with a Real Shot at Power - A Buy-on-Weakness Trade
Solid cash flow, a shareholder-friendly payout, and a strategic push into electricity make CVX a pragmatic long with measured upside.
Chevron offers a blend of defensive cash generation and optionality. Recent quarterly cash flow (Q3 2025 op cash flow $9.39B) and a generous dividend ...
Ingles Markets — Buy the Dip: This Discount Looks Temporary
Solid cash flow, consistent dividend and tangible real-estate backing make IMKTA a tactical long with defined risk controls
Ingles Markets (IMKTA) is trading below recent highs despite steady operating cash flow, positive net income and a conservative balance sheet anchored...
Rio Tinto: Price Has Risen — Still a Buy for Income+Event-Driven Upside
Actionable long with defined entry, stop and two-tier targets around M&A and commodity tailwinds
Rio Tinto has run hard over the last year but fundamentals and near-term catalysts - from merger chatter to iron-ore / copper demand dynamics and a he...
AutoZone: Buy the December Dip — Durable Cash Flow + Share-Holder Friendly Returns
A tactical long after a sharp pullback — entry, stops and realistic targets laid out for a 3–6 month swing.
AutoZone pulled back into a cleaner, lower-risk entry after a strong fiscal quarter and continued cash generation. The company’s scale (6,666 U.S. s...
Gilead: Solid GARP Story but Momentum Cooling - Reduce to Neutral, Trade Plan Inside
Strong cash flow and pipeline keep Gilead attractive, but near-term momentum and headline risk argue for a tactical downgrade.
Gilead (GILD) remains a durable Growth-at-a-Reasonable-Price (GARP) biotech pick thanks to high-margin HIV/hepatitis franchises, expanding oncology as...
Pfizer Rebound: Income Support + Pipeline News Point to a 1–3 Month Upside Trade
High yield, improving cash flow and fresh clinical wins make PFE an actionable long with defined entry, stop and targets.
Pfizer (PFE) looks like a classic income + recovery trade right now: a ~6.7% annualized dividend yield, improving operating cash flow (Q3 2025 operati...